Definium Therapeutics’ (DFTX) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Definium Therapeutics (NASDAQ:DFTX) in a research note issued to investors on Friday,Benzinga reports. They currently have a $75.00 price objective on the stock, up from their prior price objective of $73.00.

DFTX has been the topic of several other research reports. Canaccord Genuity Group set a $58.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Wells Fargo & Company started coverage on shares of Definium Therapeutics in a research report on Monday, July 27th. They set an “overweight” rating and a $68.00 target price on the stock. JonesTrading increased their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research note on Wednesday, June 24th. Finally, Stifel Nicolaus boosted their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Definium Therapeutics presently has an average rating of “Buy” and an average price target of $55.00.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $46.14 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The company has a market cap of $4.60 billion, a price-to-earnings ratio of -13.45 and a beta of 2.23. The stock has a fifty day moving average price of $37.89 and a two-hundred day moving average price of $25.87. Definium Therapeutics has a 52-week low of $8.70 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Analysts predict that Definium Therapeutics will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares in the company, valued at $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Definium Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Definium Therapeutics in the 4th quarter valued at approximately $117,000. Caxton Associates LLP acquired a new stake in shares of Definium Therapeutics in the 3rd quarter valued at approximately $126,000. Finally, Mercer Global Advisors Inc. ADV boosted its stake in Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after acquiring an additional 2,079 shares during the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.